781 |
CALCIUM VOLTAGE-GATED CHANNEL AUXILIARY SUBUNIT ALPHA2DELTA 1 |
CACNA2D1 |
CACNA2 |
CACNL2A |
CCHL2A |
LINC01112 |
lncRNA-N3 |
114204 |
1399 |
ENSG00000153956 |
OTTHUMG00000023622 |
P54289 |
CA2D1_HUMAN |
Voltage-dependent calcium channel subunit alpha-2-1 |
Voltage-dependent calcium channel subunit alpha-2/delta-1 |
Voltage-gated calcium channel subunit alpha-2/delta-1 |
MHS3 |
Voltage-dependent calcium channel subunit delta-1 |
DIHYDROPYRIDINE-SENSITIVE L-TYPE, CALCIUM CHANNEL ALPHA-2/DELTA SUBUNITS PRECURSOR. [SOURCE:UNIPROT/SWISSPROT;ACC:P54289] |
PA86 |
Voltage-gated calcium channel alpha-2/delta-1 |
T84316 |
Target Subclass | AuxillaryTransportUnit |
Target Subclass | CACNA2D |
Transmembrane Helix Count | 1 |
Target Main Class | Transporters |
Human Readable Name | DRUGGABLE GENOME |
Target Class | Transporters |
Target Subclass | TC:8.A.18.1.1 |
Gene Biotype | PROTEIN_CODING |
ION CHANNEL |
DRUGGABLE GENOME |
activator (activating) |
Trial Name | - |
Novel drug target | Established target |
inhibitor (inhibitory) |
Novel drug target | Established target |
Trial Name | - |
modulator |
Direct Interaction | yes |
Mechanism of Interaction | Voltage-gated calcium channel alpha2/delta subunit 1 modulator |
inhibitor (inhibitory) |
Trial Name | enalapril + felodipine,Lexxel |
Novel drug target | Established target |
Trial Name | felodipine ,Plendil |
inhibitor (inhibitory) |
modulator |
Trial Name | Depomed |
Novel drug target | Established target |
Trial Name | gabapentin,N/ |
inhibitor (inhibitory) |
Trial Name | aliskiren + amlodipine,Tekamlo |
Novel drug target | Established target |
Trial Name | amlodipine besylate,Norvasc |
modulator |
Mechanism of Interaction | Voltage-gated calcium channel modulator |
Direct Interaction | yes |
inhibitor (inhibitory) |
Novel drug target | Established target |
Trial Name | - |
modulator |
Mechanism of Interaction | Voltage-gated calcium channel modulator |
Direct Interaction | yes |
Trial Name | XP13512 |
modulator |
Direct Interaction | yes |
Mechanism of Interaction | Voltage-gated calcium channel modulator |
n/a |
Trial Name | Safinamide |
Novel drug target | Established target |
blocker (inhibitory) |
Mechanism of Interaction | Voltage-gated calcium channel blocker |
Direct Interaction | yes |
modulator |
Direct Interaction | yes |
Mechanism of Interaction | Voltage-gated calcium channel modulator |
CACNA2D1 | Ensembl Gene Name |
Gene Biotype | PROTEIN_CODING |
781 | Entrez Gene Id |
P54289 | Uniprot Accession |
CACNA2D1 | Gene Symbol |
Target Subclass | AuxillaryTransportUnit |
Target Subclass | CACNA2D |
Transmembrane Helix Count | 1 |
CACNA2D1 | Display Id |
ENSG00000153956 | Ensembl Gene Id |
DIHYDROPYRIDINE-SENSITIVE L-TYPE, CALCIUM CHANNEL ALPHA-2/DELTA SUBUNITS PRECURSOR. [SOURCE:UNIPROT/SWISSPROT;ACC:P54289] | Description |
Human Readable Name | DRUGGABLE GENOME |
DRUGGABLE GENOME |
CACNA2D1 | Gene Symbol |
Target Class | Transporters |
Target Subclass | TC:8.A.18.1.1 |
PA86 | PharmGKB ID |
ENSG00000153956 | Gene Symbol |
CACNA2D1 | Ensembl Id |
DRUGGABLE GENOME |
CCHL2A | GENE_SYMBOL |
MHS3 | GENE_SYMBOL |
CACNA2D1 | GENE_SYMBOL |
CACNA2D1 | TTD Gene Abbreviation |
T84316 | TTD Target ID |
Voltage-dependent calcium channel subunit alpha-2/delta-1 | Gene Name |
P54289 | UniProt ID |
ION CHANNEL |